We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+61.95%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$297M
AUM Growth
+$23.7M
Cap. Flow
-$42.8M
Cap. Flow %
-14.42%
Top 10 Hldgs %
96.75%
Holding
19
New
–
Increased
–
Reduced
1
Closed
3

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$19.2M
2
GOSS icon
Gossamer Bio
GOSS
+$18M
3
OMEG
Omega Alpha SPAC Class A Ordinary Shares
OMEG
+$4.97M
4
EPIX
ESSA Pharma
EPIX
+$597K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGO
1
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$109M 36.57%
3,018,737
– –
REPL icon
2
Replimune Group
REPL
$814M
$91.4M 30.82%
3,361,806
-926,348
-22% -$19.2M
NUVB icon
3
Nuvation Bio
NUVB
$2.24B
$28.9M 9.75%
15,072,340
– –
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$16M 5.39%
597,723
– –
ALPN
5
DELISTED
Alpine Immune Sciences Inc
ALPN
$14.9M 5.03%
2,029,580
– –
CINC
6
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$7.85M 2.65%
560,985
– –
KRON
7
DELISTED
Kronos Bio
KRON
$6.19M 2.08%
3,818,283
– –
IMA
8
ImageneBio Inc
IMA
$63.1M
$5.98M 2.02%
187,427
– –
PRTK
9
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.69M 1.24%
1,971,241
– –
THRX
10
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$3.54M 1.19%
711,479
– –
SANA icon
11
Sana Biotechnology
SANA
$885M
$3.33M 1.12%
843,750
– –
IMUX icon
12
Immunic
IMUX
$182M
$2.5M 0.84%
178,816
– –
SPRB
13
Spruce Biosciences
SPRB
$119M
$2.33M 0.79%
28,814
– –
SYRS
14
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$902K 0.3%
251,270
– –
JNCE
15
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$306K 0.1%
275,513
– –
SNTI icon
16
Senti Biosciences Holdings
SNTI
$12.6M
$276K 0.09%
19,579
– –
EPIX
17
DELISTED
ESSA Pharma
EPIX
– –
-328,196
Closed -$597K
GOSS icon
18
Gossamer Bio
GOSS
$66.5M
– –
-1,500,000
Closed -$18M
OMEG
19
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
– –
-501,000
Closed -$4.97M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2022 Portfolio in Review

As of Q4 2022, Omega Fund Management held 19 positions worth $297M, up 8.7% from $273M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Omega Fund Management withdrew a net $42.8M in Q4 2022, closing 3 positions and reducing 1 holding. Its most notable exit was Gossamer Bio, an estimated $18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

  • Omega Fund Management's biggest Q4 2022 reduction was Replimune Group, cutting an estimated $19.2M.
  • Omega Fund Management fully exited Gossamer Bio in Q4 2022, selling an estimated $18M.
  • Omega Fund Management's ten largest holdings make up 97% of its $297M portfolio in Q4 2022.
  • Omega Fund Management opened 0 new positions and closed 3 in Q4 2022.
  • Omega Fund Management's portfolio value rose 8.7% quarter-over-quarter to $297M.

Based on Omega Fund Management's 13F filing for Q4 2022, filed 13 Feb 2023.